Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) Peptide
SPG20
Reactivity: Mammalian
Host: Synthetic
BP, WB, IHC
Catalog No. ABIN936930
Quick Overview for Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) Peptide (ABIN936930)
Target
SPG20
(Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
Origin
Mammalian
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Peptide Type
- Synthetic
-
Sequence
- ASWVSWGLVK GAEITGKAIQ KGASKLRERI QPEEKPVEVS PAVTKGLYIA
-
Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of SPG20 antibody,
Alternative Names: SPG20 control peptide, SPG20 antibody Blocking Peptide, Anti-SPG20 Blocking Peptide, Spastic Paraplegia 20 Blocking Peptide, Troyer Syndrome Blocking Peptide, KIAA0610 Blocking Peptide, SPARTIN Blocking Peptide, TAHCCP1 Blocking Peptide, SPG20, SPG-20, SPG 20, SPG-20 Blocking Peptide, SPG 20 Blocking Peptide
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C long term.
-
-
- SPG20 (Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
-
Background
- This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified.
-
Molecular Weight
- 73 kDa
Target
-
You are here:
